On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer and Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science and Research, GO2 for Lung Cancer Blood-based testing has become increasingly common in cancer care. In addition to routine [...]
For people diagnosed with lung cancer, receiving a second opinion can be an important step in confirming treatment decisions or opting for a new approach to treatment. In Mary Burlie’s case, getting a second opinion changed everything. Although her [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]